Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep592 | Obesity and cardiovascular endocrinology | ECE2015

Relationship between thyroid hormone status and concomitant medication in hyperlipidaemic patients with statin induced adverse effects

Berta Eszter , Zsiros Noemi , Nagy Endre , Paragh Gyorgy , Bodor Miklos

Statins are effective treatment for the prevention of cardiovascular diseases and used extensively worldwide. However, adverse effects induced by statins are the major barrier of maximalising cardiovascular risk reduction. Hypothyroidism and administration of drugs metabolised on the same cytochrome P450 (CYPP450) pathways where statin biotransformation occurs represent a significant risk factor for statin induced adverse effects including myopathy. Simvastatin, atorvastatin a...

ea0016p497 | Obesity | ECE2008

Insulin resistance, atherogenic dyslipidemia and other atherogenic factors in simple obesity and obesity with Acanthosis nigricans (an) in childhood

Ilyes Istvan , Felszeghy Eniko , Varadi Zita , Seres Ildiko , Paragh Gyorgy

The aim of the study was to investigate insulin resistance, dyslipidemia and atherogenic factors influencing HDL functions in symple obesity (SO) and obesity with acanthosis nigricans (OAN). Althogether 37 children with obesity, 17 girls and 20 boys, 19 with SO and 18 with OAN, were included into the study. Their age was 14.2±1.8 years and BMI was 35.9±6.1 kg/m2.Fasting glucose (FG), insulin (INS) were measured and HOMA-IR was calcul...

ea0056p1095 | Thyroid (non-cancer) | ECE2018

Serum chemerin and other dyslipidemia markers in patients with autoimmune thyroiditis

Berta Eszter , Harangi Mariann , Varga Viktoria E , Lorincz Hajnalka , Seres Ildiko , Halmi Sandor , Nagy Endre V , Paragh Gyorgy , Bodor Miklos

Aim: Chemerin, a recently discovered adipokine produced by the adipose tissue and liver, along with other atherosclerosis markers, was associated lately with metabolic syndrome and acts as chemoattractant for immune cells may also regulate immune cell properties. Autoimmune Hashimoto’s thyroiditis even with sTSH levels corrected to be within the normal range values may be accompanied by dyslipidemia presenting increased total-C, TG, LDL-C, and Lp(a), all of which are pote...

ea0081ep400 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Association of chemerin and serum advanced glycation end products in patients with autoimmune thyroiditis

Bak-Csiha Sara , Halmi Sandor , Hutkai David , Molnar Istvan , Katko Monika , Lőrincz Hajnalka , Harangi Mariann , Paragh Gyorgy , Nagy Endre , Bodor Miklos , Eszter Berta

Background: Hypothyroidism due to autoimmune thyroiditis leads to atherogenic lipid profile and metabolic changes. The formation of advanced glycation end products (AGEs) increases with hyperglycemia, hyperlipidemia and oxidative stress. Degradation of AGEs after AGEs-receptor 1-mediated intracellular uptake and renal clearance of soluble AGEs generated by certain cells like macrophages play a crucial role in the decrement of circulating AGEs level. Chemerin is an adipokine pr...

ea0014p221 | (1) | ECE2007

Associations between thyroid function parameters and adipokines in euthyroid individuals

Bajnok Laszlo , Seres Ildiko , Varga Zsuzsa , Jeges Sara , Peti Attila , Karanyi Zsolt , Juhasz Attila , Csongradi Eva , Mezosi Emese , Nagy Endre V , Paragh Gyorgy

Adipose tissue secreted hormonal mediators, adipokines play pivotal roles in the regulation of, among others, central nervous and immune systems influencing body weight, insulin action and inflammatory responses. The aim of our present study was to investigate possible associations of thyroid function with plasma levels of three of known adipokines, i.e. leptin, adiponectin and resistin in 74 Caucasian subjects without any endocrine diseases or related therapy. In order to cre...

ea0081p583 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Waist-to-height ratio is a predictor of weight loss with Gelesis200 treatment for people with overweight or obesity having prediabetes or type 2 diabetes in the LIGHT-UP study

Luzi Livio , Greenway Frank , Miller Sam , Matejkova Erika , McLean Barry , Zmuda Witold , Bogdanski Pawel , Arciszewska Malgorzata , Sjodin Anders , Salz Judith , Bochenek-Mularczyk Anna , Lewy-Alterbaum Lorena , Butcher Michael , Paragh Gyorgy , Davis Yvonne , Wilding John , Golub Howard , Leider Harry , Zohar Yishai , Sannino Alessandro , Calderon Henry , Heshmati Hassan

Introduction: Methods to predict clinically meaningful weight loss can help tailor treatment for people with overweight or obesity. LIGHT-UP (NCT03058029), is a multicenter, double-blind, randomized, placebo-controlled study over 25 weeks including 254 people with prediabetes or type 2 diabetes (127 each in the Gelesis200 and placebo arms) with a body mass index between 27 and 40 kg/m2, which demonstrated that Gelesis200 offers a compelling new potential approach in...